Crystalline form VII of cabergoline, i.e., 1 ((6 - alilergolin - 8beta - yl) - carbonyl) - 1 - (3-dimethylaminopropyl) - 3-ethylurea, a process for producing such form VII, and a Pharmaceutical composition that comprises

摘要

Disclosed is a Crystalline form VII of cabergoline, a Pharmaceutical composition containing it and Process for its preparation. The process may include a mixing procedure that uses the form I or mixture of forms I and VII of cabergoline in a Solvent at a temperature super Ior to precipitation.Cabergoline is an ErgoLine derivative that interacts with the dopamine D2 receptor and is equipped with various useful Pharmaceutical activities. It is used in the treatment of hyperprolactinemia, disorders of the central nervous system (CNS) and other related diseases. The form VII of cabergoline exhibits a significant inhibitory effect on prolactin.Cabergoline is also active, alone or in combination in the treatment of reversible obstructive Airway diseases, to control intraocular pressure and for the treatment of glaucoma. It is also used in the Veterinary Field, as agent for antiprolactina and drastically reduce the Proliferation of Vertebrate animals.The VII is particularly useful in the treatment of Parkinson's Disease (PD), Restless legs syndrome (RLS), Treatment of diseases such as Progressive Supranuclear Palsy (PSP) and multiple system atrophy (MSA).